Dezhan HealthCare Co Ltd (000813) Fair Value & Analysis
Healthcare · CN · Market cap 6.5B CNY (≈ $964M) · ISIN CNE000000VV8
What is Dezhan HealthCare Co Ltd really worth?
Below-average quality, and trading another 209% above our fair value of ¥1.11.
Risks
Fair value as of: Aug 28, 2026
From 1 valuation models · updated 7 days ago
Share price +0.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥1.39). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (¥0.7300 to ¥1.39) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range ¥2.08 – ¥5.17 · fair‑value band ¥0.7300 – ¥1.39 · the ¥3.43 price screens above the ¥1.11 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Aug 28, 2026.
Analysis
Dezhan HealthCare Co Ltd (000813) currently trades at ¥3.43, while our model-based Fair Value estimate is ¥1.11, implying the stock looks roughly 209.0% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 93/100, which puts the evidence level at low.
Over the trailing twelve months, Dezhan HealthCare Co Ltd generated revenue of 396M CNY at a net margin of −90.3%. Revenue declined 0.7% year over year. It earns a return on equity of −9.0%. The balance sheet holds a net cash position of 2.5B CNY. Fundamentals as of Aug 28, 2026
Our scenario range runs from ¥0.7300 (bear case) to ¥1.39 (bull case); at ¥3.43, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −68%, 000813 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when 000813 reaches fair value
Put 000813 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China.
Full company description
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, and hydroxyurea tablets and colchicine tablet. It also involved in the provision of biological peptides, industrial hemp, and medical service business. The company was founded in 1980 and is based in Beijing, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Dezhan HealthCare Co Ltd reported revenue of 397M CNY in FY2025 versus 734M CNY in FY2021, a compound −14.3%/yr. Reported net income was −345M CNY in FY2025.
000813 screens 209% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Dezhan HealthCare Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Dezhan HealthCare Co Ltd (000813) overvalued or undervalued?
What is the fair value of 000813?
What is the quality score of 000813?
What is the revenue of Dezhan HealthCare Co Ltd (000813)?
What is the net profit margin of 000813?
Does Dezhan HealthCare Co Ltd pay a dividend?
Watch Dezhan HealthCare Co Ltd in the live analysis
One click puts Dezhan HealthCare Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.